Insilico Medicine: Expands AI-Driven CNS Research Collaboration with Yuanyi Biotech, with Total Potential Value Reaching Up to $94.75 Million

MarsBitNews · 2026-03-26T05:30:24+00:00

Insilico Medicine and Yuanyi Biotech have reached an AI-driven research and development collaboration to jointly develop novel drug candidates for neurological diseases, with a transaction value potentially reaching up to $94.75 million.

MarsBitNews

2026-03-26 05:30:24

Abstract generation in progress

Mars Finance News, March 26 — Yingxi Intelligent announced on the Hong Kong Stock Exchange that it has reached an expanded AI-driven R&D collaboration with Tenacia Biotechnology (Hong Kong) Co., Limited (“Yuan Yi Biotech”). According to the terms of the agreement, both parties will use generative AI to develop an innovative candidate molecule with specific properties targeting challenging neurological diseases, and advance it to the preclinical candidate drug (PCC) stage to meet differentiated clinical needs. The total transaction amount for this expanded collaboration could reach up to $94.75 million. Yingxi Intelligent is expected to receive recent payments and milestone payments from Yuan Yi Biotech. (Company Announcement)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.